Stocktoria
Valion Bio, Inc. VBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-11-11
Valion Bio, Inc. statistics & valuation
Market cap$1.8M
P / B0.1×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | 0.3% | 24.4% | 16.2% | -3.0% |
| Operating margin | — | -573.8% | -701.1% | -548.8% | -448.1% |
| Net margin | — | -725.0% | -701.0% | -548.7% | -675.7% |
| FCF margin | — | -734.0% | -733.8% | -485.3% | — |
| Return on assets | -28.1% | -201.5% | -159.9% | -171.8% | -56.5% |
| Return on equity | -52.9% | -223.1% | -230.3% | -278.1% | -64.0% |
| Current ratio | 20.13 | 9.70 | 3.32 | 2.83 | 11.72 |
| Revenue growth | — | -33.7% | -36.1% | 46.4% | — |
Source: SEC EDGAR filings · CIK 0001787740 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.